Department of Ophthalmology, California Pacific Medical Center, San Francisco, Calif., USA.
Can J Ophthalmol. 2010 Aug;45(4):352-8. doi: 10.3129/i10-081.
Corticosteroids constitute the first line of therapy for patients with noninfectious ocular inflammatory disease. We review factors contributing to the clinical effectiveness of various corticosteroid preparations in patients with uveitis and discuss practical aspects regarding treatment indications, when to administer various agents, and how best to dose and monitor for both treatment and adverse effects. Topically administered corticosteroids are typically indicated for the treatment of anterior uveitis, whereas periocular or intravitreal agents are employed most often in the management of intermediate or posterior intraocular inflammation. Patients with vision-threatening uveitis, bilateral inflammation, or uveitis occurring in the setting of systemic involvement may require oral or intravenous administration of corticosteroids. Noncorticosteroid immunosuppressive agents play an important role in limiting the toxic effects of long-term corticosteroid use.
皮质类固醇是治疗非感染性眼部炎症性疾病患者的一线药物。我们回顾了各种皮质类固醇制剂在葡萄膜炎患者中的临床疗效的影响因素,并讨论了关于治疗适应证、何时给予各种药物以及如何最佳地进行剂量调整和监测以治疗和预防不良反应的实际问题。局部皮质类固醇通常适用于治疗前葡萄膜炎,而眼周或玻璃体内制剂则常用于治疗中间或后葡萄膜炎。对于威胁视力的葡萄膜炎、双侧炎症或在全身受累的情况下发生的葡萄膜炎患者,可能需要口服或静脉内给予皮质类固醇。非皮质类固醇免疫抑制剂在限制长期皮质类固醇使用的毒性作用方面发挥着重要作用。